Anna Waszkielewicz

Dr. Anna Waszkielewicz

Department of Bioorganic Chemistry, Chair of Organic Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, 30-688 Krakow, Poland
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2014 in Journal of Applied Genetics
Verified
Journal Article
Open access
PDF file
KSKarolina Słoczyńska
Karolina Słoczyńska
BPBeata Powroźnik
Beata Powroźnik
EPElżbieta Pękala
Elżbieta Pękala
AWAnna Waszkielewicz
Anna Waszkielewicz
Mutagenicity refers to the induction of permanent changes in the DNA sequence of an organism, which may result in a heritable change in the characteristics of living systems. Antimutagenic agents are able to counteract the effects of mutagens. This group of agents includes both natural and synthetic compounds. Based on their mechanism of action among antimutagens, several classes of compounds may be distinguished. These are compounds with antioxidant activity; compounds that inhibit the activation of mutagens; blocking agents; as well as compounds characterized with several modes of action. It was reported previously that several antitumor compounds act through the antimutagenic mechanism. Hence, searching for antimutagenic compounds represents a rapidly expanding field of cancer research. It may be observed that, in recent years, many publications were focused on the screening of both natural and synthetic compounds for their beneficial muta/antimutagenicity profile. Thus, the present review attempts to give a brief outline on substances presenting antimutagenic potency and their possible mechanism of action. Additionally, in the present paper, a screening strategy for mutagenicity testing was presented and the characteristics of the most widely used antimutagenicity assays were described.

1 March 2013 in Current Medicinal Chemistry
Verified
Journal Article
Open access
PDF file
AWAnna Waszkielewicz
Anna Waszkielewicz
AGAgnieszka Gunia-Krzyżak
Agnieszka Gunia-Krzyżak
NSN. Szkaradek
N. Szkaradek
KSKarolina Słoczyńska
Karolina Słoczyńska
SKS. Krupinska
S. Krupinska
HMH. Marona
H. Marona
Ion channel targeted drugs have always been related with either the central nervous system (CNS), the peripheral nervous system, or the cardiovascular system. Within the CNS, basic indications of drugs are: sleep disorders, anxiety, epilepsy, pain, etc. However, traditional channel blockers have multiple adverse events, mainly due to low specificity of mechanism of action. Lately, novel ion channel subtypes have been discovered, which gives premises to drug discovery process led towards specific channel subtypes. An example is Na+ channels, whose subtypes 1.3 and 1.7-1.9 are responsible for pain, and 1.1 and 1.2 – for epilepsy. Moreover, new drug candidates have been recognized. This review is focusing on ion channels subtypes, which play a significant role in current drug discovery and development process. The knowledge on channel subtypes has developed rapidly, giving new nomenclatures of ion channels. For example, Ca2+ channels are not any more divided to T, L, N, P/Q, and R, but they are described as Cav1.1-Cav3.3, with even newer nomenclature α1A-α1I and α1S. Moreover, new channels such as P2X1-P2X7, as well as TRPA1-TRPV1 have been discovered, giving premises for new types of analgesic drugs.

14 August 2014 in Chemical Biology & Drug Design
Verified
Journal Article
Closed access
PDF file
AWAnna Waszkielewicz
Anna Waszkielewicz
KPKarolina Pytka
Karolina Pytka
ARAnna Rapacz
Anna Rapacz
EWElżbieta Wełna
Elżbieta Wełna
MJMonika Jarzyna
Monika Jarzyna
HMHenryk Marona
Henryk Marona

10 November 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KPKarolina Pytka
Karolina Pytka
APAnna Partyka
Anna Partyka
MJMagdalena Jastrzebska-Wiesek
Magdalena Jastrzebska-Wiesek
ASAgata Siwek
Agata Siwek
MGMonika Głuch-Lutwin
Monika Głuch-Lutwin
AWAnna Wesołowska
Anna Wesołowska
The aim of this study was to further characterize pharmacological properties of two phenylpiperazine derivatives: 1-{2-[2-(2,6-dimethlphenoxy)ethoxy]ethyl}-4-(2-methoxyphenyl)piperazynine hydrochloride (HBK-14) and 2-[2-(2-chloro-6-methylphenoxy)ethoxy]ethyl-4-(2- methoxyphenyl)piperazynine dihydrochloride (HBK-15) in radioligand binding and functional in vitro assays as well as in vivo models. Antidepressant-like properties were investigated in the forced swim test (FST) in mice and rats. Anxiolytic-like activity was evaluated in the four-plate test in mice and elevated plus maze test (EPM) in rats. Imipramine and escitalopram were used as reference drugs in the FST, and diazepam was used as a standard anxiolytic drug in animal models of anxiety. Our results indicate that HBK-14 and HBK-15 possess high or moderate affinity for serotonergic 5-HT2, adrenergic α1, and dopaminergic D2 receptors as well as being full 5-HT1A and 5-HT7 receptor antagonists. We also present their potent antidepressant-like activity (HBK-14—FST mice: 2.5 and 5 mg/kg; FST rats: 5 mg/kg) and (HBK-15—FST mice: 1.25, 2.5 and 5 mg/kg; FST rats: 1.25 and 2.5 mg/kg). We show that HBK-14 (four-plate test: 2.5 and 5 mg/kg; EPM: 2.5 mg/kg) and HBK-15 (four-plate test: 2.5 and 5 mg/kg; EPM: 5 mg/kg) possess anxiolytic-like properties. Among the two, HBK-15 has stronger antidepressant-like properties, and HBK-14 displays greater anxiolytic-like activity. Lastly, we demonstrate the involvement of serotonergic system, particularly 5-HT1A receptor, in the antidepressant- and anxiolytic-like actions of investigated compounds.

1 October 2011 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
AWAnna Waszkielewicz
Anna Waszkielewicz
AGAgnieszka Gunia-Krzyżak
Agnieszka Gunia-Krzyżak
KSKarolina Słoczyńska
Karolina Słoczyńska
HMH. Marona
H. Marona
Neuropathic pain is a kind of pain related with functional abnormality of neurons. Despite large progress in pharmacotherapy, neuropathic pain is still considered an unmet need. Nowadays, there are few drugs registered for this condition, such as pregabalin, gabapentin, duloxetine, carbamazepine, and lidocaine. Among them, pregabalin, gabapentin and carbamazepine are well known antiepileptic drugs. Among the group of new antiepileptic drugs, which are addressed to 1% of human world population suffering from seizures, it turned out that 30% of the seizures resistant to pharmacotherapy has not enough market to justify the costs of drug development. Therefore, it is already a phenomenon that researchers turn their projects toward a larger market, related with possible similar mechanism. Anticonvulsant mechanism of action is in the first place among primary indications for drugs revealing potential analgesic activity. Therefore, many drug candidates for epilepsy, still in preclinical stage, are being evaluated for activity in neuropathic pain. This review is focusing on antiepileptic drugs, which are evaluated for their analgesic activity in major tests related with neuropathic pain. Relation between structure, mechanism of action and result in tests such as the Chung model (spinal nerve ligation SNL), the Bennett model (chronic constriction injury of sciatic nerve CCI) and other tests are considered. The first examples are carbamazepine, gabapentin, and lacosamide as drugs well established in epilepsy market as well as drug candidates such as valnoctamide, and other valproic acid derivatives, novel biphenyl pyrazole derivatives, etc. Moreover, clinical efficacy related with listed animal models has been discussed.

1 August 2013 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
AWAnna Waszkielewicz
Anna Waszkielewicz
AGAgnieszka Gunia-Krzyżak
Agnieszka Gunia-Krzyżak
NSN. Szkaradek
N. Szkaradek
KPKarolina Pytka
Karolina Pytka
ASA. Siwek
A. Siwek
HMH. Marona
H. Marona